• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison between follitropin-delta and follitropin-alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms!

作者信息

Montenegro Gouveia Susana, Lispi Monica, D'Hooghe Thomas Mary

机构信息

Merck Darmstadt: Merck KGaA, Darmstadt, Germany.

Merck Darmstadt: Merck KGaA, Darmstadt, Germany.

出版信息

Reprod Biomed Online. 2022 Sep;45(3):623-624. doi: 10.1016/j.rbmo.2022.03.034. Epub 2022 Apr 9.

DOI:10.1016/j.rbmo.2022.03.034
PMID:35863940
Abstract
摘要

相似文献

1
Comparison between follitropin-delta and follitropin-alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms!在辅助生殖技术（ART）背景下，比较卵泡刺激素δ和卵泡刺激素α用于卵巢刺激时，只有在双臂治疗中都允许起始剂量个体化，这样的比较才具有科学合理性和临床相关性！
Reprod Biomed Online. 2022 Sep;45(3):623-624. doi: 10.1016/j.rbmo.2022.03.034. Epub 2022 Apr 9.
2
Response to: Comparison between follitropin delta and follitropin alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms!回复：在辅助生殖技术背景下，对于卵泡刺激素δ和卵泡刺激素α进行卵巢刺激的比较，只有在双臂研究中都允许起始剂量个体化时，才在科学上合理且具有临床相关性！
Reprod Biomed Online. 2022 Sep;45(3):625. doi: 10.1016/j.rbmo.2022.03.025. Epub 2022 Apr 6.
3
Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.个体化起始剂量的卵泡刺激素 delta 可降低总体 OHSS 风险和/或需要额外预防干预的风险：三个刺激周期的累积数据。
Reprod Biomed Online. 2019 Apr;38(4):528-537. doi: 10.1016/j.rbmo.2018.12.032. Epub 2018 Dec 23.
4
A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.一项随机对照临床试验，旨在对卵泡刺激素 delta 进行个体化剂量方案进行临床验证，以用于亚洲体外受精/卵胞浆内单精子注射患者的卵巢刺激。
Hum Reprod. 2021 Aug 18;36(9):2452-2462. doi: 10.1093/humrep/deab155.
5
Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa.确定能提供与 150IU/天卵泡刺激素阿尔法相当的卵巢反应的卵泡刺激素德尔塔剂量。
Reprod Biomed Online. 2020 Oct;41(4):616-622. doi: 10.1016/j.rbmo.2020.07.006. Epub 2020 Jul 15.
6
Ovulation induction with minimal dose of follitropin alfa: a case series study.最小剂量卵泡刺激素α诱导排卵：病例系列研究。
Reprod Biol Endocrinol. 2011 Oct 24;9:142. doi: 10.1186/1477-7827-9-142.
7
Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.重组人促卵泡生成素α新质量标准对卵巢刺激的效果：既往研究的荟萃分析
BioDrugs. 2009;23(1):37-42. doi: 10.2165/00063030-200923010-00004.
8
Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.Corifollitropin alfa 与 follitropin beta 在接受 ICSI 的反应不良者中的比较：一项随机对照试验。
Hum Reprod. 2015 Feb;30(2):432-40. doi: 10.1093/humrep/deu301. Epub 2014 Dec 9.
9
[Pharmacological profile, clinical efficacy, and safety of Follitropin Delta produced by recombinant DNA technology in a human cell line (REKOVELLE PEN for S.C. Injection 12 μg, 36 μg, 72 μg)].[重组DNA技术在人细胞系中生产的促卵泡素δ（注射用REKOVELLE PEN，规格12μg、36μg、72μg）的药理特性、临床疗效及安全性]
Nihon Yakurigaku Zasshi. 2022;157(1):76-84. doi: 10.1254/fpj.21079.
10
Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.随机、评估者盲、抗缪勒管激素分层、剂量反应试验在接受卵泡刺激素 δ 控制性卵巢刺激的日本体外受精/胞浆内精子注射患者中进行。
Fertil Steril. 2021 Jun;115(6):1478-1486. doi: 10.1016/j.fertnstert.2020.10.059. Epub 2020 Dec 4.

引用本文的文献

1
The influence of the pharmaceutical industry on the development of gonadotrophins and ovarian stimulation protocols in assisted reproductive technologies.制药行业对辅助生殖技术中促性腺激素及卵巢刺激方案发展的影响。
Front Endocrinol (Lausanne). 2025 Apr 4;16:1536844. doi: 10.3389/fendo.2025.1536844. eCollection 2025.
2
The most appropriate indicators of successful ovarian stimulation.成功进行卵巢刺激的最恰当指标。
Reprod Biol Endocrinol. 2025 Jan 9;23(Suppl 1):5. doi: 10.1186/s12958-024-01331-6.
3
Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
促卵泡激素 δ 在体外受精/胞浆内单精子注射周期中卵巢刺激的疗效和安全性：系统评价与荟萃分析。
J Ovarian Res. 2024 Mar 14;17(1):60. doi: 10.1186/s13048-024-01372-w.
4
Algorithm vs. clinical experience: controlled ovarian stimulations with follitropin-delta and individualised doses of follitropin-alpha/beta.算法与临床经验：使用重组促卵泡素δ及个体化剂量的重组促卵泡素α/β进行控制性卵巢刺激
Reprod Fertil. 2024 Feb 1;5(1). doi: 10.1530/RAF-23-0045.
5
Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series.连续三天意外给予72微克促卵泡素-Δ对低反应者似乎并无危险：病例系列报道
J Clin Med. 2023 Aug 10;12(16):5202. doi: 10.3390/jcm12165202.
6
Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?卵泡刺激素生物制品：效价能预测临床疗效吗？
Int J Mol Sci. 2023 May 19;24(10):9020. doi: 10.3390/ijms24109020.